KR20190013846A - 비-조현병성 환자에서 음성 증상을 치료하기 위한 조성물 및 방법 - Google Patents

비-조현병성 환자에서 음성 증상을 치료하기 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20190013846A
KR20190013846A KR1020187036656A KR20187036656A KR20190013846A KR 20190013846 A KR20190013846 A KR 20190013846A KR 1020187036656 A KR1020187036656 A KR 1020187036656A KR 20187036656 A KR20187036656 A KR 20187036656A KR 20190013846 A KR20190013846 A KR 20190013846A
Authority
KR
South Korea
Prior art keywords
compound
weeks
subject
therapeutically effective
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187036656A
Other languages
English (en)
Korean (ko)
Inventor
레미 루트링거
마이클 데이비슨
Original Assignee
미쓰비시 타나베 파마 코퍼레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 미쓰비시 타나베 파마 코퍼레이션 filed Critical 미쓰비시 타나베 파마 코퍼레이션
Priority to KR1020237043697A priority Critical patent/KR20240005110A/ko
Publication of KR20190013846A publication Critical patent/KR20190013846A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020187036656A 2016-05-25 2017-05-23 비-조현병성 환자에서 음성 증상을 치료하기 위한 조성물 및 방법 Ceased KR20190013846A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237043697A KR20240005110A (ko) 2016-05-25 2017-05-23 비-조현병성 환자에서 음성 증상을 치료하기 위한 조성물 및 방법

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662341590P 2016-05-25 2016-05-25
US62/341,590 2016-05-25
PCT/US2017/034030 WO2017205393A1 (en) 2016-05-25 2017-05-23 Compositions and methods for treating negative symptoms in non-schizophrenic patients

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237043697A Division KR20240005110A (ko) 2016-05-25 2017-05-23 비-조현병성 환자에서 음성 증상을 치료하기 위한 조성물 및 방법

Publications (1)

Publication Number Publication Date
KR20190013846A true KR20190013846A (ko) 2019-02-11

Family

ID=58794265

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187036656A Ceased KR20190013846A (ko) 2016-05-25 2017-05-23 비-조현병성 환자에서 음성 증상을 치료하기 위한 조성물 및 방법
KR1020237043697A Ceased KR20240005110A (ko) 2016-05-25 2017-05-23 비-조현병성 환자에서 음성 증상을 치료하기 위한 조성물 및 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237043697A Ceased KR20240005110A (ko) 2016-05-25 2017-05-23 비-조현병성 환자에서 음성 증상을 치료하기 위한 조성물 및 방법

Country Status (9)

Country Link
US (2) US20190216793A1 (cg-RX-API-DMAC7.html)
EP (1) EP3463356A1 (cg-RX-API-DMAC7.html)
JP (3) JP2019516756A (cg-RX-API-DMAC7.html)
KR (2) KR20190013846A (cg-RX-API-DMAC7.html)
CN (3) CN113908156A (cg-RX-API-DMAC7.html)
PH (1) PH12018502445A1 (cg-RX-API-DMAC7.html)
SG (2) SG11201810358YA (cg-RX-API-DMAC7.html)
TW (2) TWI851224B (cg-RX-API-DMAC7.html)
WO (1) WO2017205393A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210119803A (ko) * 2020-03-25 2021-10-06 주식회사 케이티앤지 카트리지 및 이를 포함하는 에어로졸 생성 장치

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9458130B2 (en) 2014-12-02 2016-10-04 Minerva Neurosciences, Inc. Compositions and methods for treating schizophrenia
US11464744B2 (en) 2017-06-21 2022-10-11 Minerva Neurosciences, Inc. Gastro-resistant controlled release oral dosage forms
MX2021002017A (es) * 2018-08-21 2021-04-28 Minerva Neurosciences Inc Uso de roluperidona para tratar sintomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroproteccion.
TWI879755B (zh) * 2020-02-20 2025-04-11 日商田邊三菱製藥股份有限公司 魯哌啶酮用於治療負性症狀及疾病、增加神經可塑性及促進神經保護的用途
US11957675B2 (en) * 2021-02-09 2024-04-16 Xenon Pharmaceuticals Inc. Methods and uses for treating anhedonia
US20240212824A1 (en) * 2022-12-21 2024-06-27 Woebot Labs, Inc. Administering a digital therapeutic using a device interface to treat anxiety or depression

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0300203A3 (en) * 2000-02-29 2006-01-30 Mitsubishi Pharma Corp Novel cyclic amide derivatives, and pharmaceutical compositions containing same
TW200616608A (en) * 2004-07-09 2006-06-01 Forest Laboratories Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
KR20080093453A (ko) * 2006-02-07 2008-10-21 미쓰비시 타나베 파마 코퍼레이션 4-아실아미노피리딘 유도체 매개된 신경조직발생
KR20080089279A (ko) * 2007-03-30 2008-10-06 미쓰비시 타나베 파마 코퍼레이션 우울증의 예방 및/또는 치료제
KR101867633B1 (ko) * 2010-07-20 2018-06-15 미쓰비시 타나베 파마 코퍼레이션 정신분열증을 치료하기 위한 시클릭 아미드 유도체의 사용 방법
CA2805904C (en) * 2010-07-20 2022-06-21 Cyrenaic Pharmaceuticals, Inc. Use of cyclic amide derivatives to treat sigma receptor-mediated disorders
US8937900B2 (en) * 2010-07-20 2015-01-20 Qualcomm Incorporated Enhancing pilot channel transmission in TD-SCDMA multicarrier systems using secondary carrier frequencies
US9737531B2 (en) * 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
WO2015174534A1 (ja) * 2014-05-16 2015-11-19 武田薬品工業株式会社 含窒素複素環化合物
US9458130B2 (en) * 2014-12-02 2016-10-04 Minerva Neurosciences, Inc. Compositions and methods for treating schizophrenia

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210119803A (ko) * 2020-03-25 2021-10-06 주식회사 케이티앤지 카트리지 및 이를 포함하는 에어로졸 생성 장치

Also Published As

Publication number Publication date
TWI820001B (zh) 2023-11-01
CN109689055A (zh) 2019-04-26
TW202335672A (zh) 2023-09-16
SG10202011470UA (en) 2021-01-28
US20230190726A1 (en) 2023-06-22
CN113908156A (zh) 2022-01-11
PH12018502445A1 (en) 2019-09-09
WO2017205393A1 (en) 2017-11-30
US20190216793A1 (en) 2019-07-18
CN113694065A (zh) 2021-11-26
TWI851224B (zh) 2024-08-01
JP2019516756A (ja) 2019-06-20
EP3463356A1 (en) 2019-04-10
TW201808288A (zh) 2018-03-16
JP2025000921A (ja) 2025-01-07
KR20240005110A (ko) 2024-01-11
SG11201810358YA (en) 2018-12-28
JP2022188185A (ja) 2022-12-20

Similar Documents

Publication Publication Date Title
KR20190013846A (ko) 비-조현병성 환자에서 음성 증상을 치료하기 위한 조성물 및 방법
US20250000881A1 (en) Treatment of treatment resistant depression with psilocybin
US20240115550A1 (en) Treatment of mental disorders
US20240108602A1 (en) Treatment of mental disorders
WO2024160391A1 (en) Treatment of mental disorders
CN120712084A (zh) 用于治疗母乳喂养母亲的精神障碍的5-甲氧基-n,n-二甲基色胺
US20180244623A1 (en) N-methyl-D-aspartate Receptor (NMDAR) Potentiators, Pharmaceutical Compositions, And Uses Related Thereto
JP2022526101A (ja) 重水素化デキストロメトルファン及びキニジンを使用して統合失調症の陰性症状を治療する方法
CN117377470A (zh) 美维达林和其他d1正向别构调节剂在幻觉和痴呆相关精神病的治疗中的用途
EP4337182A1 (en) Reducing side effects of nmda receptor antagonists
TW201211021A (en) Methods of use of cyclic amide derivatives to treat schizophrenia
WO2025068714A1 (en) Pharmaceutical compositions comprising 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt)
CN120641095A (zh) 精神障碍的治疗
KR20250005172A (ko) 정신 장애의 치료
Zornig the beauty of~ relief.

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0601 Decision of rejection after re-examination

St.27 status event code: N-2-6-B10-B17-rex-PX0601

X601 Decision of rejection after re-examination
T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)

R13 Change to the name of applicant or owner recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R13-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)